Pfizer Inc. (NYSE:PFE) Receives $28.13 Average Target Price from Brokerages

Shares of Pfizer Inc. (NYSE:PFE) have earned a consensus recommendation of “Hold” from the eighteen brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, twelve have given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $28.1765.

A number of equities research analysts recently issued reports on PFE shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a research note on Wednesday. Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. UBS Group reissued a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Finally, Sanford C. Bernstein reissued a “market perform” rating and set a $30.00 price target on shares of Pfizer in a research note on Friday, October 31st.

Pfizer Price Performance

PFE stock opened at $24.64 on Thursday. Pfizer has a 1 year low of $20.92 and a 1 year high of $27.99. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock’s 50 day moving average price is $24.74 and its 200 day moving average price is $24.33. The firm has a market cap of $140.09 billion, a P/E ratio of 13.11, a PEG ratio of 0.81 and a beta of 0.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, sell-side analysts expect that Pfizer will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio is currently 91.49%.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in PFE. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer during the 1st quarter worth $27,000. Curio Wealth LLC raised its position in shares of Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,098 shares during the period. North Capital Inc. purchased a new position in shares of Pfizer in the 1st quarter worth $28,000. Bayforest Capital Ltd purchased a new position in shares of Pfizer in the 1st quarter worth $28,000. Finally, Harbor Asset Planning Inc. purchased a new position in shares of Pfizer in the 2nd quarter worth $29,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.